These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38115195)

  • 1. Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors.
    Zhao Y; Sanghavi K; Roy A; Murthy B; Bello A; Aras U; Vezina H
    Clin Pharmacol Ther; 2024 Mar; 115(3):488-497. PubMed ID: 38115195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
    Zhang J; Cai J; Bello A; Roy A; Sheng J
    J Clin Pharmacol; 2019 Oct; 59(10):1415-1424. PubMed ID: 31115908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
    Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
    Bei D; Osawa M; Uemura S; Ohno T; Gobburu J; Roy A; Hasegawa M
    Cancer Sci; 2020 Feb; 111(2):528-535. PubMed ID: 31773815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
    Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
    Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
    Zhao Y; Hu Z; Bathena SP; Keidel S; Miller-Moslin K; Statkevich P; Bello A; Roy A; Suryawanshi S
    Clin Cancer Res; 2024 Jul; 30(14):3050-3058. PubMed ID: 38295151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
    Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
    Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.
    Sheng J; Zhang J; Baudelet C; Roy A
    J Clin Pharmacol; 2021 Aug; 61(8):1045-1053. PubMed ID: 33501654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
    Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
    J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
    Puszkiel A; Bianconi G; Pasquiers B; Balakirouchenane D; Arrondeau J; Boudou-Rouquette P; Bretagne MC; Salem JE; Declèves X; Vidal M; Kramkimel N; Guegan S; Aractingi S; Huillard O; Alexandre J; Wislez M; Goldwasser F; Blanchet B
    Br J Cancer; 2024 May; 130(11):1866-1874. PubMed ID: 38532102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
    Zhao X; Suryawanshi S; Hruska M; Feng Y; Wang X; Shen J; Vezina HE; McHenry MB; Waxman IM; Achanta A; Bello A; Roy A; Agrawal S
    Ann Oncol; 2017 Aug; 28(8):2002-2008. PubMed ID: 28520840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.
    Jamois C; Gibiansky E; Gibiansky L; Chavanne C; Morcos PN; McIntyre C; Barrett M; Lundberg L; Zharkov A; Boehnke A; Frey N
    Clin Pharmacol Ther; 2021 Nov; 110(5):1261-1272. PubMed ID: 34041738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
    Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
    Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
    Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
    J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.